The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and partners issued new appropriate use criteria recommending 18F-FDG PET/CT as the preferred nuclear medicine test for diagnosing fever of unknown origin in adults and children, providing guidance on six clinical scenarios to aid physicians in complex cases.
A PET radiotracer can assess the presence of a biomarker that indicates the level of tumor aggressiveness in neuroendocrine neoplasms.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has launched a new education program designed to educate, train, and develop individuals with a pharmacy or chemistry background in the production and release of clinical radiopharmaceuticals.
Thomas J. Ruth, PhD, FRSC, FSRS, a scientist known for his contributions to nuclear medicine and nuclear chemistry, has been named as this year’s recipient of the Georg Charles de Hevesy Nuclear Pioneer Award.
Read MoreRichard L. Wahl, MD, the Elizabeth E. Mallinckrodt Professor and head of radiology at Washington University School of Medicine in St. Louis, has been named 2021-22 president of the Society of Nuclear Medicine and Molecular Imaging.
Read More
The Society of Nuclear Medicine and Molecular Imaging named 17 new SNMMI Fellows during a plenary session at the society’s 2021 Annual Meeting, held virtually from June 11-15.
Read More
On June 7, the U.S. FDA approved aducanumab (Aduhelm) for the treatment of patients in the early stages of Alzheimer’s disease. Aducanumab selectively targets and removes beta amyloid plaques. SNMMI officials say they recognize the importance of this landmark approval, which was based on data from the ENGAGE trial.
Read More
SNMMI and 62 organizations, representing more than 1 million healthcare providers, thanked Congress for its past efforts on physician reimbursement and requested the inclusion of specific provisions in future legislation.
Read More